Esperion Therapeutics (ESPR) Competitors $0.80 -0.05 (-5.86%) Closing price 04:00 PM EasternExtended Trading$0.81 +0.01 (+1.37%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. XNCR, ABCL, CDXC, KALV, REPL, BCYC, ANAB, COGT, VECT, and SIONShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Xencor (XNCR), AbCellera Biologics (ABCL), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Cogent Biosciences (COGT), VectivBio (VECT), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Xencor AbCellera Biologics ChromaDex KalVista Pharmaceuticals Replimune Group Bicycle Therapeutics AnaptysBio Cogent Biosciences VectivBio Sionna Therapeutics Esperion Therapeutics (NASDAQ:ESPR) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor ESPR or XNCR? Esperion Therapeutics received 122 more outperform votes than Xencor when rated by MarketBeat users. However, 73.13% of users gave Xencor an outperform vote while only 70.27% of users gave Esperion Therapeutics an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes63170.27% Underperform Votes26729.73% XencorOutperform Votes50973.13% Underperform Votes18726.87% Is ESPR or XNCR more profitable? Esperion Therapeutics has a net margin of -29.37% compared to Xencor's net margin of -232.77%. Esperion Therapeutics' return on equity of 0.00% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-29.37% N/A -10.77% Xencor -232.77%-30.92%-21.74% Which has better valuation & earnings, ESPR or XNCR? Xencor has lower revenue, but higher earnings than Esperion Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$259.57M0.63-$209.25M-$0.80-1.02Xencor$127.23M4.13-$126.09M-$3.06-2.41 Do insiders & institutionals have more ownership in ESPR or XNCR? 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ESPR or XNCR? Esperion Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 663.13%. Xencor has a consensus target price of $29.50, suggesting a potential upside of 299.46%. Given Esperion Therapeutics' higher possible upside, equities analysts clearly believe Esperion Therapeutics is more favorable than Xencor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media prefer ESPR or XNCR? In the previous week, Xencor had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 6 mentions for Xencor and 2 mentions for Esperion Therapeutics. Xencor's average media sentiment score of 0.52 beat Esperion Therapeutics' score of 0.21 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ESPR or XNCR? Esperion Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. SummaryXencor beats Esperion Therapeutics on 10 of the 19 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.33M$6.47B$5.32B$8.43BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-1.289.0626.7719.71Price / Sales0.63254.27390.22118.35Price / CashN/A65.8538.2534.62Price / Book-0.216.416.754.50Net Income-$209.25M$143.98M$3.23B$248.32M7 Day Performance5.38%1.97%1.55%-0.09%1 Month Performance-11.91%4.09%12.22%12.89%1 Year Performance-65.59%-2.83%16.71%7.33% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.5583 of 5 stars$0.80-5.9%$6.25+678.3%-64.6%$159.15M$259.57M-1.25200XNCRXencor3.7001 of 5 stars$8.77+5.3%$29.50+236.4%-68.4%$624.00M$110.49M-2.74280Positive NewsABCLAbCellera Biologics2.7477 of 5 stars$2.06+1.5%$7.50+264.1%-48.3%$614.75M$28.83M-3.38500Gap UpCDXCChromaDex2.308 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120KALVKalVista Pharmaceuticals4.2973 of 5 stars$12.18+2.4%$24.83+103.9%+2.2%$605.54MN/A-3.35100News CoveragePositive NewsREPLReplimune Group3.8633 of 5 stars$7.86+1.9%$19.43+147.2%+51.9%$605.34MN/A-2.56210News CoveragePositive NewsEarnings ReportOptions VolumeGap UpBCYCBicycle Therapeutics3.7791 of 5 stars$8.60+3.1%$25.00+190.7%-62.7%$595.14M$25.72M-2.61240Gap UpANABAnaptysBio3.3452 of 5 stars$20.03+2.2%$35.88+79.1%-13.1%$592.37M$91.28M-3.29100News CoveragePositive NewsCOGTCogent Biosciences2.3605 of 5 stars$5.13+6.7%$14.29+178.5%-37.1%$584.08MN/A-2.0780News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeSIONSionna TherapeuticsN/A$12.90+4.7%$38.50+198.4%N/A$569.20MN/A0.0035News CoverageAnalyst DowngradeGap Down Related Companies and Tools Related Companies Xencor Competitors AbCellera Biologics Competitors ChromaDex Competitors KalVista Pharmaceuticals Competitors Replimune Group Competitors Bicycle Therapeutics Competitors AnaptysBio Competitors Cogent Biosciences Competitors VectivBio Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts